Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00734578 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of SPD503 in Combination With Psychostimulants
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 461
- Enrollment target
NCT00734578 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 461 participants.
The verdict
NCT00734578, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 461 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of SPD503 in subjects with ADHD when co-administered with psychostimulants in children and adolescents aged 6-17 years with a diagnosis of ADHD with a sub-optimal, partial response to stimulants.
Interventions
- DRUG Placebo
- DRUG SPD503-AM
- DRUG SPD503-PM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 461 participants |
| Start Date | 2008-09-02 |
| Est. Completion | 2009-12-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00734578
The ClinicalTrials.gov registry entry for NCT00734578 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 461 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00734578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00734578 about?
NCT00734578 is a clinical study titled "Efficacy and Safety of SPD503 in Combination With Psychostimulants". The purpose of this study is to assess the efficacy and safety of SPD503 in subjects with ADHD when co-administered with psychostimulants in children and adolescents aged 6-17 years with a diagnosis of ADHD with a sub-optimal, partial response to stimulants.
What is the current status of trial NCT00734578?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 461 participants. The study started on 2008-09-02. Estimated completion is 2009-12-10.
What interventions are being tested in trial NCT00734578?
The interventions under investigation include: Placebo (DRUG), SPD503-AM (DRUG), SPD503-PM (DRUG).
Who is sponsoring clinical trial NCT00734578?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.